OBJECTIVE: To estimate activity and safety of trabectedin 1.5 mg/m2 IV over 24 hours every 3 weeks (1 cycle) in uterine leiomyosarcoma. METHODS: Patients with chemotherapy naive, advanced, persistent or recurrent uterine leiomyosarcoma, acceptable organ function and PS≤2 were eligible. A two-stage design was utilized. Three responses were required in the first stage to initiate the second stage; the target sample size was 40 for the combined stages. If the true response rate was 10%, the study design provided a 95% chance of correctly classifying the treatment as "inactive." Conversely, if the true response rate was 30%, then the average probability of correctly classifying the treatment as active would be 90%. RESULTS: Twenty patients were eligible and evaluable. The median number of cycles was 10 (123 total cycles, range 2-29). The number of patients with partial responses was 2 (10%; 95% confidence interval of 1.2%-31.7%). Response durations were 3.3 and 5.7 months. Ten patients had stable disease (50%). The median progression-free survival (PFS) and overall survival were 5.8 months and greater than 26.1 months (median not reached), respectively. Observed grade 3/4 toxicity included: neutropenia 16/20 (1 infection); thrombocytopenia 3/20; metabolic 3/20; anemia, gastrointestinal and vascular 1/20 each. There were no treatment related deaths nor cases of liver failure. CONCLUSIONS: Although a second stage of accrual was not indicated based on the overall response rate, the drug was well tolerated.
OBJECTIVE: To estimate activity and safety of trabectedin 1.5 mg/m2 IV over 24 hours every 3 weeks (1 cycle) in uterine leiomyosarcoma. METHODS:Patients with chemotherapy naive, advanced, persistent or recurrent uterine leiomyosarcoma, acceptable organ function and PS≤2 were eligible. A two-stage design was utilized. Three responses were required in the first stage to initiate the second stage; the target sample size was 40 for the combined stages. If the true response rate was 10%, the study design provided a 95% chance of correctly classifying the treatment as "inactive." Conversely, if the true response rate was 30%, then the average probability of correctly classifying the treatment as active would be 90%. RESULTS: Twenty patients were eligible and evaluable. The median number of cycles was 10 (123 total cycles, range 2-29). The number of patients with partial responses was 2 (10%; 95% confidence interval of 1.2%-31.7%). Response durations were 3.3 and 5.7 months. Ten patients had stable disease (50%). The median progression-free survival (PFS) and overall survival were 5.8 months and greater than 26.1 months (median not reached), respectively. Observed grade 3/4 toxicity included: neutropenia 16/20 (1 infection); thrombocytopenia 3/20; metabolic 3/20; anemia, gastrointestinal and vascular 1/20 each. There were no treatment related deaths nor cases of liver failure. CONCLUSIONS: Although a second stage of accrual was not indicated based on the overall response rate, the drug was well tolerated.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Bradley J Monk; Thomas J Herzog; Stanley B Kaye; Carolyn N Krasner; Jan B Vermorken; Franco M Muggia; Eric Pujade-Lauraine; Alla S Lisyanskaya; Anatoly N Makhson; Janusz Rolski; Vera A Gorbounova; Prafull Ghatage; Mariusz Bidzinski; Keng Shen; Hextan Yuen-Sheung Ngan; Ignace B Vergote; Joo-Hyun Nam; Youn Choi Park; Claudia A Lebedinsky; Andrés M Poveda Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: F J Major; J A Blessing; S G Silverberg; C P Morrow; W T Creasman; J L Currie; E Yordan; M F Brady Journal: Cancer Date: 1993-02-15 Impact factor: 6.860
Authors: Ali Mahdavi; Bradley J Monk; Jennifer Ragazzo; Mark I Hunter; Scot E Lentz; Steven A Vasilev; Krishnansu S Tewari Journal: Int J Gynecol Cancer Date: 2009-08 Impact factor: 3.437
Authors: Martee L Hensley; John A Blessing; Koen Degeest; Ovadia Abulafia; Peter G Rose; Howard D Homesley Journal: Gynecol Oncol Date: 2008-04-18 Impact factor: 5.482
Authors: Rebecca C Arend; Michael D Toboni; Allison M Montgomery; Robert A Burger; Alexander B Olawaiye; Bradley J Monk; Thomas J Herzog Journal: Oncologist Date: 2018-08-23
Authors: Martee L Hensley; Brigitte A Barrette; Klaus Baumann; David Gaffney; Anne L Hamilton; Jae-Weon Kim; Johanna U Maenpaa; Patricia Pautier; Nadeem Ahmad Siddiqui; Anneke M Westermann; Isabelle Ray-Coquard Journal: Int J Gynecol Cancer Date: 2014-11 Impact factor: 3.437
Authors: Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo Journal: Br J Pharmacol Date: 2019-12-23 Impact factor: 8.739
Authors: Julia A Elvin; Laurie M Gay; Rita Ort; Joseph Shuluk; Jennifer Long; Lauren Shelley; Ronald Lee; Zachary R Chalmers; Garrett M Frampton; Siraj M Ali; Alexa B Schrock; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Richard Frank Journal: Oncologist Date: 2017-03-10
Authors: Martee L Hensley; Shreyaskumar R Patel; Margaret von Mehren; Kristen Ganjoo; Robin L Jones; Arthur Staddon; Daniel Rushing; Mohammed Milhem; Bradley Monk; George Wang; Sharon McCarthy; Roland E Knoblauch; Trilok V Parekh; Robert G Maki; George D Demetri Journal: Gynecol Oncol Date: 2017-06-24 Impact factor: 5.482